252 related articles for article (PubMed ID: 37028835)
1. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Bruni C; Campochiaro C; de Vries-Bouwstra JK
Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
[TBL] [Abstract][Full Text] [Related]
2. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
3. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
5. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
[TBL] [Abstract][Full Text] [Related]
6. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.
Higuero Sevilla JP; Memon A; Hinchcliff M
Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
8. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care.
Mendoza FA; Allawh T; Jimenez SA
Clin Exp Rheumatol; 2023 Aug; 41(8):1704-1712. PubMed ID: 37382458
[TBL] [Abstract][Full Text] [Related]
11. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
13. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
[TBL] [Abstract][Full Text] [Related]
14. Management of systemic sclerosis-associated interstitial lung disease.
Roofeh D; Jaafar S; Vummidi D; Khanna D
Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
16. Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality.
Volkmann ER; Tashkin DP; Roth MD; Goldin J; Kim GHJ
Chest; 2022 May; 161(5):1310-1319. PubMed ID: 34896093
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Raghu G; Montesi SB; Silver RM; Hossain T; Macrea M; Herman D; Barnes H; Adegunsoye A; Azuma A; Chung L; Gardner GC; Highland KB; Hudson M; Kaner RJ; Kolb M; Scholand MB; Steen V; Thomson CC; Volkmann ER; Wigley FM; Burlile D; Kemper KA; Knight SL; Ghazipura M
Am J Respir Crit Care Med; 2024 Jan; 209(2):137-152. PubMed ID: 37772985
[No Abstract] [Full Text] [Related]
19. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.
Vonk MC; Smith V; Sfikakis PP; Cutolo M; Del Galdo F; Seibold JR
Autoimmun Rev; 2021 Dec; 20(12):102978. PubMed ID: 34718159
[TBL] [Abstract][Full Text] [Related]
20. [Modern drug therapy for systemic sclerosis associated interstitial lung disease].
Aringer M; Koschel D; Krause A; Schneider U; Gläser S
Dtsch Med Wochenschr; 2022 Feb; 147(4):179-186. PubMed ID: 34861699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
